SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CleanSpark, Inc. is a bitcoin mining technology company, which engages in the management of data centers. Its operations include College Park, Norcross, Washington, Sandersville, Dalton, and Massena. The company was founded by S. Matthew Schultz and Bryan Huber on October 15, 1987 and is headquartered in Henderson, NV.

Cleanspark Inc

CleanSpark ($CLSK) is trending due to heightened speculation around its AI/HPC pivot and anticipation for its upcoming earnings report. Community members are actively debating the company's potential in the AI sector, citing land acquisition and infrastructure advantages. Bullish sentiment suggests a possible short squeeze amid positive analyst ratings, while bears cite mixed financials and sector competition.

SMX (Security Matters) Plc is a holding company, which engages in the provision of authentication solutions. It offers brand protection, authentication, and track and trace technology. The company was founded by Haggai Alon on July 1, 2022 and is headquartered in Dublin, Ireland.

SMX (Security Matters) Plc

SMX (Security Matters) Public Ltd Co - Ordinary Shares - Class A

SMX is trending as traders discuss a potential short squeeze, fueled by a high cost to borrow and news around partnerships. Community members are pointing to technical patterns and high short interest, while others debate the company's history of reverse stock splits. Overall, discussion centers around whether SMX can sustain its momentum or if it will succumb to dilution concerns.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

Marathon Digital ($MARA) is trending as investors debate its correlation with Bitcoin's price movements and overall performance compared to its peers. The community is actively discussing executive compensation and insider selling, questioning the company's future direction amid Bitcoin's volatility. Some traders express frustration with $MARA's price action, while others see it as an opportunity for a potential short squeeze or long-term accumulation.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategy is trending as traders discuss its correlation to Bitcoin's price movements and potential short squeeze opportunities. Community members are debating the impact of institutional actions, particularly JPM's, and the possibility of Strategy being removed from certain indexes. Bullish and bearish sentiments clash as some anticipate a rally while others foresee further declines.

Zscaler, Inc. engages in the provision of a cloud-based internet security platform. It offers Zero Trust Exchange, Zscaler Client Connector, Zscaler Internet Access, Zscaler Private Access, Zscaler B2B, Zscaler Cloud Protection, and Zscaler Digital Experience. The company was founded by Jagtar Singh Chaudhry and K. Kailash in September 2007 and is headquartered in San Jose, CA.

Zscaler Inc

Zscaler is trending following its earnings release, with discussions centered on whether the results justify the stock's valuation and future growth potential. While the company reported strong revenue growth and positive guidance, community members are debating if it can sustain its premium valuation, especially compared to competitors. Some traders are closely watching for a potential breakout while others express concerns about profitability and the impact of IV crush on options.

Kohl's Corp. engages in the operation of family-oriented department stores. Its business line includes apparel, footwear, and accessories for women, men, and children, home products, beauty products, and accessories. The stores generally carry a consistent merchandise assortment with some differences attributable to regional preferences. The company was founded in 1962 and is headquartered in Menomonee Falls, WI.

Kohl`s Corp.

Kohl's Corp

Kohl's ($KSS) is trending as traders debate whether it can maintain momentum after a recent surge. The community is discussing potential short squeezes, citing high short interest and real estate value, while also weighing concerns about retail sector weakness and potential resistance levels. Some see a longer-term recovery play if it can stabilize margins and improve cash flow.

Workday, Inc. engages in the provision of development of enterprise cloud applications for finance and human resources. It delivers financial management, human capital management and analytics applications designed for companies, educational institutions, and government agencies. The company was founded by David A. Duffield and Aneel Bhusri in 2005 and is headquartered in Pleasanton, CA.

Workday Inc - Ordinary Shares - Class A

Workday Inc

Workday is trending as investors digest its Q3 earnings, which beat expectations, though revenue guidance is viewed as inline rather than exceeding forecasts. The community is focused on fresh customer wins, industry demand, and subscription backlog that are contributing to overall strength. Some traders are pointing to Workday taking market share from competitors, while others discuss analyst ratings and potential support levels.

Grayscale Bitcoin Mini Trust ETF - Common units of fractional undivided beneficial interest

Grayscale Bitcoin Mini Trust ETF

Grayscale Bitcoin Mini Trust ETF is trending as Bitcoin flirts with key price levels, sparking debate about market direction. Community discussion revolves around potential breakouts, resistance levels, and whether current market conditions signal bullish or bearish sentiment. Some traders are citing Tom Lee's comments on MSTR and keeping a close eye on possible impacts from the US government.

One Stop Systems, Inc. engages in the design, manufacture, and marketing of computing modules and systems targeting edge deployments. It deals with the design and manufacture of high-performance customized computer and flash arrays, in-flight entertainment, and connectivity and value-added reseller with minimal customization. It operates through the OSS and OSS Europe segments. The company was founded by Stephen D. Cooper and Mark Gunn in 1998 and is headquartered in Escondido, CA.

One Stop Systems Inc

One Stop Systems is trending due to increasing investor interest in edge computing and AI, with community members highlighting the company's low market cap relative to its potential. Discussions revolve around potential catalysts like contract announcements and institutional buying, with some drawing comparisons to competitors and expressing optimism about long-term growth in the AI and defense sectors. The stock experienced a spike and halt, fueling speculation about insider information or imminent news.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta is trending due to its potential as a settlement and interoperability rail, boasting high throughput and compliance-first architecture, drawing comparisons to established players like Chainlink and USD Coin. The community is discussing its positioning as financial plumbing and its capacity to handle regulated assets with signals from Eric Schmidt and Google Cloud further fueling interest. Community members also suggest the asset is about to explode.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Traders Purchase Large Volume of Call Options on Esperion Therapeutics (NASDAQ:ESPR)

Esperion Therapeutics, Inc. (NASDAQ:ESPR - Get Free Report) was the target of unusually large options trading activity on Tuesday. Stock traders acquired 4,601 call options on the stock. This...

Esperion Therapeutics (NASDAQ:ESPR) Coverage Initiated at Piper Sandler

Piper Sandler assumed coverage on Esperion Therapeutics in a report on Tuesday. They set an "overweight" rating and a $9.00 target price on the stock...

<ul class="summary-bullets"><li>Piper Sandler projected long-term growth backed by rising use of Esperion’s LDL-lowering therapies and expanding payer coverage.</li><li>Q3 revenue rose sharply as U.S. product sales and collaboration income continued to strengthen.</li><li>The recent Japan launch and milestones from partner Otsuka added to investor optimism about Esperion’s global expansion.</li></ul>Esperion Therapeutics shares climbed to their highest levels in nearly a year on Tuesday after a bullish initiation from Piper Sandler and fresh progress on the company’s international launch plans helped lift investor sentiment.The stock closed 16.4% higher at $3.69 on Tuesday and edged up another 0.3% in after-hours trading, also logging its best session in almost four months.&nbsp;<h2 class="st-heading-2">Piper Sandler Calls Esperion A Strong Risk-Reward Play</h2>Piper Sandler initiated coverage with an ‘Overweight’ rating and projected a potential 144% upside, describing Esperion as a strong risk-reward play supported by accelerating demand for its cholesterol-lowering drug franchise. The firm highlighted the strength of the company’s bempedoic acid–based therapies, Nexletol and Nexlizet, and said it expects continued rapid volume and sales expansion as physicians shift toward non-statin low-density lipoprotein (LDL)-lowering options, according to a report by&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://in.investing.com/news/analyst-ratings/piper-sandler-initiates-esperion-therapeutics-stock-with-overweight-rating-93CH-5124964">Investing</a>.The brokerage pointed to several drivers of long-term growth, including a wide label that covers primary prevention, evolving clinical guidelines that increasingly support the drug class, and broad payer access. A cardiologist-focused survey conducted by the firm reinforced confidence in the therapies’ adoption trajectory.Piper Sandler said it expects Esperion’s products to reach over $650 million in peak U.S. sales, with additional contributions from ex-U.S. royalties, and noted that recent agreements with generic filers provide visibility into exclusivity extending to 2040.Piper Sandler added that Esperion’s risk-reward profile is attractive, noting the stock trades at an enterprise value of roughly 10x estimated 2026 EBITDA, with high visibility into a long-term EBITDA compound annual growth rate above 30% from 2026 through 2031. This long-term view remains intact even as the company reported an EBITDA loss of $29.27 million over the last twelve months.<h2 class="st-heading-2">Esperion Posts Strong Q3 Growth</h2>Esperion reported third-quarter (Q3) total revenue of $87.3 million, an increase of 69% year-on-year, with U.S. net product revenue rising 31% year-on-year to $40.7 million. Collaboration revenue strengthened as well, supported by higher royalty sales and product supply to partners. The company reported an EBITDA loss of $29.27 million, net loss of $31.3 million, and ended the quarter with $92.4 million in cash and cash equivalents. U.S. commercial coverage expanded to more than 90% of commercial lives and over 80% of Medicare beneficiaries, and total prescription volume increased during the period.<h2 class="st-heading-2">Japan Launch Builds Global Momentum</h2>Esperion’s upward momentum comes shortly after a major international milestone. Last week, the company said that its partner Otsuka Pharmaceutical received National Health Insurance Price Listing in Japan and launched Nexletol for hypercholesterolemia and familial hypercholesterolemia. Japan represents the third largest global market for cardiovascular prevention, marking a significant expansion opportunity for Esperion’s cholesterol franchise.Under the agreement, Esperion will receive a $90 million payment tied to Otsuka’s recent regulatory and pricing achievements. The company is also eligible for additional sales milestone payments and tiered royalties of 15% to 30% on net sales in Japan.<h2 class="st-heading-2">Stocktwits Traders Signal Long-Term Confidence</h2>On Stocktwits, retail sentiment for Esperion was ‘extremely bullish’ amid ‘high’ message volume.<figure class="image"><img style="aspect-ratio:972/146;" src="https://news.stocktwits-cdn.com/espr_stock_png_0574a99904.webp" alt="espr stock.png" width="972" height="146"><figcaption>ESPR sentiment and message volume as of November 25 | Source: Stocktwits</figcaption></figure>One user said they did not see a buyout happening soon, noting that Esperion already has a growing commercial drug, additional pipeline assets and a path toward profitability.<stembedurl>https://stocktwits.com/Petey3163/message/637466961</stembedurl>Another user said they expected to remain invested for 18 to 24 months, describing cardiovascular opportunities as early and ESP-2001 as still upcoming, and added that they had built a large position and planned to hold.<stembedurl>https://stocktwits.com/Lskynrd1/message/637466633</stembedurl><a href="https://stocktwits.com/symbol/ESPR">Esperion Therapeutics’ stock</a> has risen 67% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Esperion Therapeutics Inc. logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Esperion Therapeutics Stock Hits Near 1-Year High As Wall Street Sees Strong Risk-Reward Play On Demand For Cholesterol Drug 

Piper Sandler projected long-term growth backed by rising use of Esperion’s LDL-lowering therapies and expanding payer coverage.

Equity

Esperion Therapeutics (NASDAQ:ESPR) Trading Up 4.1% - Should You Buy?

Esperion Therapeutics (NASDAQ:ESPR) Shares Up 4.1% - Still a Buy...

Esperion Partner HLS Receives Health Canada Approval For NILEMDO To Lower LDL-Cholesterol

(RTTNews) - Esperion Therapeutics, Inc. (ESPR) on Tuesday said HLS Therapeutics Inc. (HLS), its partner in Canada for NILEMDO, has received Health Canada approval to market NILEMDO for reducing...

HC Wainwright Has Positive Outlook for ESPR FY2025 Earnings

Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - HC Wainwright increased their FY2025 earnings estimates for shares of Esperion Therapeutics in a note issued to investors on Thursday...

Research Analysts Set Expectations for ESPR FY2026 Earnings

Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - HC Wainwright lifted their FY2026 earnings per share (EPS) estimates for shares of Esperion Therapeutics in a research note issued to...

Esperion Therapeutics (NASDAQ:ESPR) Trading Down 13.1% After Earnings Miss

Esperion Therapeutics (NASDAQ:ESPR) Trading Down 13.1% After Earnings Miss...

ESPR's Q3 Earnings Lag Estimates, Revenues Rise Y/Y, Stock Down

Esperion's Q3 loss widens despite a 69% jump in revenues.  Mixed results and investor jitters probably drag ESPR shares down 15%.

Esperion Therapeutics (ESPR) Reports Q3 Loss, Tops Revenue Estimates

Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of -77.78% and +4.75%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Esperion Therapeutics, Inc. is a pharmaceutical company, which engages in the development and commercialization of oral therapies for elevated low-density lipoprotein cholesterol. The firm offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.

Esperion Therapeutics Inc.

$NVDA

$AAPL

$GOOG/$GOOGL

$MSFT

Which company ends 2025 with the largest market cap?

ESPR
Esperion Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ESPR News

ESPREsperion Therapeutics Inc.